Menu Search
Equities

Merck Tbk PT

MERK:JKT

Merck Tbk PT

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (IDR)3,500.00
  • Today's Change-110.00 / -3.05%
  • Shares traded40.50k
  • 1 Year change-20.09%
  • Beta1.1258
Data delayed at least 10 minutes, as of Nov 08 2024 09:11 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in IDRIncome statement in IDRView more

Year on year Merck Tbk PT had little change in net income (from 179.84bn to 178.24bn) despite revenues that fell -14.51% from 1.12tn to 961.43bn.
Gross margin34.90%
Net profit margin13.36%
Operating margin13.43%
Return on assets13.54%
Return on equity16.95%
Return on investment16.05%
More ▼

Cash flow in IDRView more

In 2023, Merck Tbk PT increased its cash reserves by 18.19%, or 31.01bn. The company earned 203.87bn from its operations for a Cash Flow Margin of 21.21%. In addition the company used 19.90bn on investing activities and also paid 152.96bn in financing cash flows.
Cash flow per share371.20
Price/Cash flow per share9.43
Book value per share1,628.52
Tangible book value per share1,624.30
More ▼

Balance sheet in IDRView more

Merck Tbk PT uses little debt in its capital structure as supported by a debt to capital ratio of 2.47%.
Current ratio4.53
Quick ratio1.70
Total debt/total equity0.0253
Total debt/total capital0.0247
More ▼

Growth rates in IDR

Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -0.89%. Additionally when measured on a five year annualized basis, dividend per share growth is below the industry average relative to its peers, while earnings per share growth is the highest in its industry.
Div yield(5 year avg)6.04%
Div growth rate (5 year)-34.05%
Payout ratio (TTM)114.77%
EPS growth(5 years)36.67
EPS (TTM) vs
TTM 1 year ago		-22.17
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.